ENDOMETRIAL HYPERPLASTIC PROCESSES AT DIFFERENT AGES: STUDY OF CYTOKINE STATUS AND SFAS LIGAND LEVELS


Cite item

Full Text

Open Access Open Access
Restricted Access Access granted
Restricted Access Subscription or Fee Access

Abstract

Objective. To study the local and systemic levels of cytokines and sFas ligand in endometrial hyperplastic processes and polyps at reproductive and premenopausal ages. Subjects and methods. One hundred and thirty-one women were examined. The patients were divided into 6 groups according to their age and histological findings. The patients’ uterine cavity aspiration specimens and sera were used to measure the concentrations of interleukin-2, intereukin-4, tumor necrosis factor-α, and sFas ligand by solid-phase enzyme immunoassay. A p value < 0.05 was regarded as significant. Results. Significant differences were found in the concentrations of cytokines and sFas ligand in the uterine aspiration specimens from the patients with endometrial hyperplasia and polyps versus the controls of reproductive and premenopausal ages. All the groups showed signif icant differences in the uterine aspiration specimens and serum concentrations of cytokines and sFas ligand. Their concentrations were significantly higher in the uterine cavity aspiration specimens than those in the sera. There were no differences in the serum levels of cytokines and sFas in all the groups. Conclusion. Prior inflammatory diseases, intrauterine interventions, or intrauterine contraception may be a cause of local immunity dysfunction and Fas-dependent apoptosis in endometrial pathology. The determination of cytokines and sFas ligand in the uterine cavity aspiration specimens may be a useful diagnostic marker of endometrial hyperplasia and polyps.

Full Text

Restricted Access

About the authors

O. V LYSENKO

Vitebsk State Medical University

Email: lysenko_o_v@mail.ru, olgalight2008@rambler.ru

S. N ZANKO

Vitebsk State Medical University

References

  1. Бабаченко И.В. и др. Ронколейкин - рекомбинантный интерлейкин-2 человека. — СПб., 2001.
  2. Кузнецова И.В. Гиперпластические процессы эндометрия. —М., 2009.
  3. Куценко И.И. и др. Новые подходы к комплексной терапии рецидивирующих вульвовагинальных кандидозов // Врач и аптека XXI век. —2006. — № 2. — С. 24—25.
  4. Нестеров И.М., Тотолян А.А. Иммунокорригирующая терапия инфекционно-воспалительных заболеваний женской половой сферы: Практическое пособие для практикующих акушеров-гинекологов, студентов медицинских ВУЗов, врачей-интернов и клинических ординаторов. - СПб., 2007.
  5. Профилактическая нейроиммуноэндокринология / Коновалов С.С., Ильницкий А.Н., Горощаев К.И., Кветной И.М. — СПб.: Прайм-ЕВРОЗНАК, 2008.
  6. Романовский О.Ю. Гиперпластические процессы эндометрия в репродуктивном периоде (обзор литературы) // Гинекология. — 2004. —Т. 6, № 6. — С. 296—302.
  7. Тихомиров А.Л., Сарсания С.И. Современные принципы профилактики и лечения воспалительных заболеваний женских половых органов: Метод. рекомендации для врачей акушеров-гинекологов / Под ред. В.Н. Серова. -М., 2005.
  8. Anastadiadis P.G. et al. Endometrial polyps: prevalence, detection, and malignant potential in women with abnormal uterine bleeding // Eur. J. Gynaecol. Oncol. — 2000. — Vol. 21, № 2. — P. 180—183.
  9. Antunes A. Jr. et al. Endometrial polyps in pre- and postmenopausal women: factors associated with malignancy // Maturitas. — 2007. — Vol. 57, № 4. — Р. 415—421.
  10. Atasoy P. et al. Fas-mediated pathway and apoptosis in normal, hyperplastic, and neoplastic endometrium // Gynecol. Oncol. — 2003. — Vol. 91, № 2. — Р. 309—317.
  11. Clark T. J., Neelakantan D., Gupta J. K. The management of endometrial hyperplasia: an evaluation of current practice // Eur. J. Obstet. Gynecol. Reprod. Biol. — 2006. — Vol. 125, № 2. — Р. 259—264.
  12. Hu K., Zhong G., He F. Expression of estrogen receptors ERalpha and ERbeta in endometrial hyperplasia and adenocarcinoma // Int. J. Gynecol. Cancer. - 2005. Vol. 15, № 3. — Р. 537—541.
  13. Kapucuoglu N. et al. Immunohistochemical expression of PTEN in normal, hyperplastic and malignant endometrium and its correlation with hormone receptors, bcl-2, bax, and apoptotic index // Pathol. Res. Pract. — 2007. — Vol. 203, № 3. — Р. 153—162.
  14. Kusakabe K. et al. Spontaneous endometrial hyperplasia in the uteri of IL-2 receptor beta-chain transgenic mice // J. Reprod. Dev. — 2009. — Vol. 55, № 3. — P. 273—277.
  15. Novak L. et al. Incidence of endometrial carcinoma in patients with endometrial hyperplasia // Eur. J. Gynaecol. Oncol. — 2005. — Vol. 26, № 5. — P. 561—563.
  16. Rekha K. et al. Apoptosis in endometria of dysfuntional uterine bleeding women // Med. J. Malaysia. — 2005. — Vol. 60, № 1. — Р. 41—45.
  17. Sukhikh G.T. et al. Disorders in cytokine gene expression in endometrial hyperplasia and effect of hormone therapy // Bull. Exp. Biol. Med. — 2005. — Vol. 139, № 2. — P. 235—237.
  18. Tao X.J., Sayegh R.A., Isaacson K.B. Increased natural killer cells and decreased regulatory T cells are seen in complex atypical endometrial hyperplasia and well-differentiated carcinoma treated with progestins // Bull. Exp. Biol. Med. — 2010. — Vol. 41, № 1. — P. 26—32.

Supplementary files

Supplementary Files
Action
1. JATS XML

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies